• 1
    Hewitt M, Greenfield S, Stovall E. From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC: National Academies Press; 2006.
  • 2
    Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28:11171123.
  • 3
    Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001;28:555565.
  • 4
    Bianco FJ, Jr., Scardino PT, Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (“trifecta”). Urology. 2005;66(5 suppl):8394.
  • 5
    Ciezki JP, Reddy CA, Stephenson AJ, et al. The importance of serum prostate-specific antigen testing frequency in assessing biochemical and clinical failure after prostate cancer treatment. Urology. 2010;75:467471.
  • 6
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:15911597.
  • 7
    Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25:20352041.
  • 8
    Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs. observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008;299:27602769.
  • 9
    Jemal A, Ward E, Wu X, Martin HJ, McLaughlin CC, Thun MJ. Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev. 2005;14:590595.
  • 10
    Godley PA, Schenck AP, Amamoo MA, et al. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst. 2003;95:17021710.
  • 11
    Mohler J, Babaian RJ, Bahnson RR, Boston B. NCCN Practice Guidelines in Oncology: Prostate Cancer. Version 2, 2007 edition. National Comprehensive Cancer Network; 2007.
  • 12
    Salloum RG, Hornbrook MC, Fishman PA, Ritzwoller DP, O'Keeffe Rossetti MC, Elston Lafata J. Adherence to surveillance care guidelines after breast and colorectal cancer treatment with curative intent. Cancer. 2012;119:56445651.
  • 13
    Zeliadt SB, Penson DF, Albertsen PC, Concato J, Etzioni RD. Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. Cancer. 2003;98:496503.
  • 14
    Ambs A, Warren JL, Bellizzi KM, Topor M, Haffer SC, Clauser SB. Overview of the SEER–Medicare Health Outcomes Survey linked dataset. Health Care Financ Rev. 2008;29:521.
  • 15
    Carpenter WR, Howard DL, Taylor YJ, Ross LE, Wobker SE, Godley PA. Racial differences in PSA screening interval and stage at diagnosis. Cancer Causes Control. 2010;21:10711080.
  • 16
    Cohen J, Schoenbach V, Kaufman J, et al. Racial differences in clinical progression among Medicare recipients after treatment for localized prostate cancer (United States). Cancer Causes Control. 2006;17:803811.
  • 17
    Prostate. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
  • 18
    Mohler J, Amling CL, Bhanson RR. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 1, 2010 edition. National Comprehensive Cancer Network; 2010.
  • 19
    Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007;17:584590.
  • 20
    Koroukian SM, Dahman B, Copeland G, Bradley CJ. The utility of the state buy-in variable in the Medicare denominator file to identify dually eligible Medicare-Medicaid beneficiaries: a validation study. Health Serv Res. 2010;45:265282.
  • 21
    RTI International. Spatial impact factor data. Version 4, published 2011. Accessed December 18, 2011.
  • 22
    US Department of Agriculture, Economic Research Service. Persistent poverty counties, 1970-2000. Published 2004. Accessed December 18, 2011.
  • 23
    Massey DS, Denton NA. The dimensions of residential segregation. Social Forces. 1988;67:281315.
  • 24
    Rupasingha A, Goetz SJ. US county-level social capital data, 1990-2005. Published 2008; accessed December 18, 2011.
  • 25
    Cameron A, Trivedi P. Microeconomics Using Stata. College Station, TX: Stata Press; 2009.
  • 26
    Pan W. Akaike's information criterion in generalized estimating equations. Biometrics. 2001;57:120125.
  • 27
    Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol. 1994;152(5 pt 1):13581368.
  • 28
    Salz T, Weinberger M, Ayanian JZ, et al. Variation in use of surveillance colonoscopy among colorectal cancer survivors in the United States. BMC Health Serv Res. 2010;10:256.
  • 29
    Carcaise-Edinboro P, Bradley CJ, Dahman B. Surveillance mammography for Medicaid/Medicare breast cancer patients. J Cancer Surviv. 2010;4:5966.
  • 30
    Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 suppl):IV3 to IV-18.
  • 31
    Kaiser Family Foundation. Medicare Advantage Fact Sheet. Publication #2052-162012:2. Published November 30, 2012.
  • 32
    Hamilton AS, Albertsen PC, Johnson TK, et al. Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int. 2011;107:576584.